top of page

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.640 +0.010 (+0.63%)

Delayed Quote Updated: 9:39 AM EDT, Oct 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	25,491
Open	1.650
Bid (Size)	1.640 (900)
Ask (Size)	1.650 (1,100)
Prev. Close	1.630
Today's Range	1.640 - 1.655
52wk Range	1.330 - 3.100
Shares Outstanding	80,817,079
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease ↗

Today 4:02 EDT

ProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid...

Via MarketBeat

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

September 23, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

Performance

YTD	-17.6%	-17.6%
1 Month	-22.6%	-22.6%
3 Month	-9.4%	-9.4%
6 Month	-4.1%	-4.1%
1 Year	-24.1%	-24.1%

More News

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

September 09, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR to Participate in Upcoming Investor Conferences in September 2026

September 02, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Second Quarter 2026 Operating and Financial Results

August 13, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

June 25, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

June 25, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces First Quarter 2026 Operating and Financial Results

May 12, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform

May 11, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026

May 04, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors

April 30, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

Wondering what's happening in today's pre-market session? ↗

March 30, 2026

Via Chartmill

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

March 25, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Year End 2025 Operating and Financial Results

March 12, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference

March 03, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Planned Changes to Board Composition

February 09, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

January 08, 2026

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR to Participate in 8th Annual Evercore Healthcare Conference

December 01, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Third Quarter 2025 Operating and Financial Results

November 06, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025

October 20, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

October 16, 2025

Via Chartmill

ProQR to Participate in Upcoming Investor Conferences in October 2025

October 13, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 16, 2025

Via Benzinga

ProQR Announces Second Quarter 2025 Operating and Financial Results

August 07, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

ProQR Announces Upcoming Presentation at RNA Editing Summit

July 28, 2025

From ProQR Therapeutics N.V.

Via GlobeNewswire

Frequently Asked Questions

Is ProQR Therapeutics N.V. - Ordinary Shares publicly traded?

Yes, ProQR Therapeutics N.V. - Ordinary Shares is publicly traded.

What exchange does ProQR Therapeutics N.V. - Ordinary Shares trade on?

ProQR Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares?

The ticker symbol for ProQR Therapeutics N.V. - Ordinary Shares is PRQR on the Nasdaq Stock Market

What is the current price of ProQR Therapeutics N.V. - Ordinary Shares?

The current price of ProQR Therapeutics N.V. - Ordinary Shares is 1.640

When was ProQR Therapeutics N.V. - Ordinary Shares last traded?

The last trade of ProQR Therapeutics N.V. - Ordinary Shares was at 10/02/26 09:39 AM ET

What is the market capitalization of ProQR Therapeutics N.V. - Ordinary Shares?

The market capitalization of ProQR Therapeutics N.V. - Ordinary Shares is 132.56M

How many shares of ProQR Therapeutics N.V. - Ordinary Shares are outstanding?

ProQR Therapeutics N.V. - Ordinary Shares has 133M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

bottom of page